First Patient Dosed in Ph 2a Clinical Trial of GFH009 in AML
“We are excited to advance GFH009 to the next phase of clinical development, which we believe holds great promise for patients who continue to suffer with advanced and difficult to treat AML,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “As far as we know, GFH009 is the only CDK9 inhibitor in development that, as a single agent, has shown such unique and very encouraging clinical data which is the reason our hematology experts see high promise in this Phase 2a study. Treatment of the first patient in this study represents successful completion of one of several near-term potential value enhancing milestones.”
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
